IN8bio's Cash Position More Than Doubles to $27.1M, Extending Runway into H1 2027
Summary
IN8bio announced its fourth-quarter results, reporting a narrowed net loss of $4.9 million. More significantly, the company's cash position more than doubled to $27.1 million as of December 31, 2025, up from $11.1 million a year prior. This substantial increase was primarily due to the closing of a $20.1 million tranche of a private placement, a highly material financing event for a company of its size. This financing extends IN8bio's cash runway into the first half of 2027, significantly de-risking its operational outlook and providing capital for its clinical programs. The company also anticipates FDA guidance on its regulatory pathway by the second half of 2026 and expects multiple clinical and preclinical milestones throughout the year.
At the time of this announcement, INAB was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $1.17 to $7.62. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.